Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start.

ABSTRACT:

Background

Rheumatoid arthritis (RA) has a variable impact on different synovial joints, with inflammation being more commonly observed in some joints than others. Emerging evidence suggests that the anatomical variation in pathophysiology could result in differential responses to treatments across the joints, both within and between modes of action. This analysis aimed to characterize joint-specific responses to tofacitinib and methotrexate monotherapy in patients with RA.

Methods

This was a post hoc analysis of data from the phase III trial ORAL Start (NCT01039688), in methotrexate-naïve patients with RA. A paired joint pathology score (PJPS), derived from bilateral tender/swollen joint counts, was calculated. The percentage change from baseline in PJPS (%∆PJPS) and treatm

SUBMITTER: Ciurea A 

PROVIDER: S-EPMC10540368 | biostudies-literature | 2023 Sep

REPOSITORIES: biostudies-literature